Type 2 diabetes: Added benefit of canagliflozin plus metformin is not proven
Drug manufacturer's dossier provided no suitable data for any subindication
2014-11-21
(Press-News.org) The fixed combination of canagliflozin with metformin (trade name: Vokanamet) has been approved since April 2014 for adults with type 2 diabetes mellitus in whom diet and exercise do not provide adequate glycaemic control. The German Institute for Quality and Efficiency in Health Care (IQWiG) now examined in a dossier assessment whether the new drug combination offers an added benefit over the appropriate comparator therapy. No such added benefit can be derived from the dossier, however, because the manufacturer did not present any suitable data for any of the possible subindications.
IQWiG already came to the same conclusion in the assessment of canagliflozin as monotherapy and in various free combination therapies in June 2014.
Combination with further drugs possible
The fixed combination of canagliflozin and metformin can be used alone or in addition to other blood-glucose lowering drugs (including insulin) when these do not provide adequate glycaemic control. It is also an option for patients already taking the two drugs as separate tablets.
G-BA specifies appropriate comparator therapy
The Federal Joint Committee (G-BA) specified different appropriate comparator therapies for three possible different subindications: When the fixed combination is used alone, it is to be compared with the combination of a sulfonylurea (glibenclamide or glimepiride) in combination with metformin. When the fixed combination is used together with a sulfonylurea or insulin, human insulin plus metformin is to be the appropriate comparator therapy.
No added benefit claimed for two subindications
The manufacturer claimed no added benefit for the combination with insulin and the combination with a sulfonylurea because the available studies allowed neither direct nor indirect comparisons.
Comparison not only of drugs, but also of therapeutic strategies
For the comparison of canagliflozin plus metformin with a sulfonylurea in free combination with metformin, the manufacturer used data from an approval study (DIA3009) that it had already submitted for the first dossier assessment.
These data are inadequate for the derivation of an added benefit, however. Because of its design, this study not only compared the effects of two drugs with each other, but also two different therapeutic strategies. Hence possible differences in treatment results cannot be clearly attributed to the drugs or the therapeutic strategies.
G-BA decides on the extent of added benefit
The dossier assessment is part of the overall procedure for early benefit assessments according to the Act on the Reform of the Market for Medicinal Products (AMNOG) supervised by the G-BA. After publication of the manufacturer's dossier and IQWiG's assessment, the G-BA conducts a commenting procedure, which may provide further information and result in a change to the benefit assessment. The G BA then decides on the extent of the added benefit, thus completing the early benefit assessment.
INFORMATION:
An overview of the results of IQWiG's benefit assessment is given by a German-language executive summary. In addition, the website » http://www.gesundheitsinformation.de, published by IQWiG, provides easily understandable and brief German-language information on canagliflozin/Metformin.
The G-BA website contains both general English-language information on benefit assessments pursuant to §35a Social Code Book V and specific German-language information on the assessment of canagliflozin/Metformin.
More English-language information will be available soon (Sections 2.1 to 2.6 of the dossier assessment as well as subsequently published health information on » http://www.informedhealthonline.org). If you would like to be informed when these documents are available, please send an e-mail to » info@iqwig.de.
ELSE PRESS RELEASES FROM THIS DATE:
2014-11-21
Lugano/Geneva, Switzerland, 21 November 2014 - The possibilities for personalised vaccines in all types of cancer are revealed today in a lecture from Dr Harpreet Singh at the ESMO Symposium on Immuno-Oncology 2014 in Geneva, Switzerland.
"One of the biggest hurdles in cancer immunotherapy is the discovery of appropriate cancer targets that can be recognised by T-cells," said Singh, who is scientific coordinator of the EU-funded GAPVAC phase I trial which is testing personalised vaccines in glioblastoma, the most common and aggressive brain cancer. "In the GAPVAC trial ...
2014-11-21
Public health researchers from the University of Adelaide have evaluated international breast cancer guidelines, finding that there is potential to improve surveillance of breast cancer survivors from both a patient and health system perspective.
International guidelines recommend annual follow-up mammograms for every woman after treatment for early breast cancer, regardless of the risk of her cancer returning. There is also no strong evidence to support annual mammography compared with other possible mammography schedules.
In a paper published in the journal Value ...
2014-11-21
VIDEO:
Powered lower limb prosthetics hold promise for improving the mobility of amputees, but errors in the technology may also cause some users to stumble or fall. New research from the...
Click here for more information.
Powered lower limb prosthetics hold promise for improving the mobility of amputees, but errors in the technology may also cause some users to stumble or fall. New research examines exactly what happens when these technologies fail, with the goal of developing ...
2014-11-21
Bethesda, MD (Nov. 21, 2014) -- Cirrhosis and nonalcoholic fatty liver disease (NAFLD) are two serious liver conditions with limited pharmacological treatments. The December issues of AGA's journals -- Clinical Gastroenterology and Hepatology and Gastroenterology -- highlight important updates into treatments for these two debilitating diseases.
For access to any of these studies, or to speak with the study authors, please contact media@gastro.org or call 301-272-1603.
Promising Probiotic for Liver Disease
A study published in Gastroenterology1 found that, over a ...
2014-11-21
EAST LANSING, Mich. --- Don't get along with your boss? Your job performance may actually improve if the two of you can come to grips with the poor relationship.
A new study led by Michigan State University business scholars finds that workers are more motivated if they and their supervisors see eye-to-eye about a bad relationship than if they have different views about their relationship. The findings are published in the Academy of Management Journal.
"Seeing eye-to-eye about the employee-supervisor relationship is equally, if not more important than the actual quality ...
2014-11-21
SCOTTSVILLE, SOUTH AFRICA-- Worldwide, drought conditions, extreme temperatures, and high soil saline content all have negative effects on tomato crops. These natural processes reduce soil nutrient content and lifespan, result in reduced plant growth and yield, and ultimately translate to lower profits for tomato producers. As an alternative to unsustainable practices such as the use of synthetic fertilizers, producers are looking to environment-friendly soil ameliorants such as verimcompost leachate, an organic liquid produced from earthworm-digested material and casts ...
2014-11-21
TUSCON, AZ - Soil solarization, a process that uses solar radiation to rid the soil of pests, is most common in regions with high solar radiation and high temperatures during the summer season. An alternative to soil fumigation, the process is used either alone or in combination with fumigants. To accomplish solarization, solar radiation is used to passively heat moist soil covered with clear plastic sheeting, with the goal of increasing soil temperatures to the point where they are lethal to soilborne organisms. The effectiveness of solarization is based on the actual ...
2014-11-21
Quebec City, November 21, 2014--Scientists from Université Laval, the University of British Columbia and the University of Oxford have discovered a natural resistance gene against spruce budworm in the white spruce. The breakthrough, reported in The Plant Journal, paves the way to identifying and selecting naturally resistant trees to replant forests devastated by the destructive pest.
A research team composed of professors Éric Bauce, Joerg Bohlmann and John Mackay as well as their students and postdocs discovered the gene in spruces that had remained relatively ...
2014-11-21
Employees who work at small, locally owned businesses have the highest level of loyalty to their employers -- and for rural workers, size and ownership of their company figure even more into their commitment than job satisfaction does, according to Baylor University researchers.
Higher levels of commitment are associated with less absenteeism, lower turnover and less seeking of jobs outside the company. The study -- "Small, local and loyal: How firm attributes affect workers' organizational commitment" -- is published in the journal Local Economy.
"It's an interesting ...
2014-11-21
LA JOLLA, CA - November 20, 2014 - Scientists at The Scripps Research Institute (TSRI) have discovered how one gene is essential to hearing, uncovering a cause of deafness and suggesting new avenues for therapies.
The new study, published November 20 in the journal Neuron, shows how mutations in a gene called Tmie can cause deafness from birth. Underlining the critical nature of their findings, researchers were able to reintroduce the gene in mice and restore the process underpinning hearing.
"This raises hopes that we could, in principle, use gene-therapy approaches ...
LAST 30 PRESS RELEASES:
[Press-News.org] Type 2 diabetes: Added benefit of canagliflozin plus metformin is not proven
Drug manufacturer's dossier provided no suitable data for any subindication
